Resources Repository
-
ReportPublication 2017DCP3: Improving Health and Reducing Poverty
This report from the World Bank is the ninth and final volume of the Disease …
This report from the World Bank is the ninth and final volume of the Disease Control Priorities, Third Edition (DCP3) series. It provides an overview of the findings and methods explored in the first eight volumes, placing them within a framework that identifies an efficient pathway toward essential universal health coverage through the implementation of 21 essential packages that include health interventions and fiscal and intersectoral policies. The Disease Control Priorities Network (DCP) promotes and…
Evidence Synthesis | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Economics/Finance | Maternal/Reproductive Health | Mental Health | Infectious Diseases | Costing Methods | Health Outcomes | Child/Nutrition | Chronic Disease/Risk | Injuries/Accidents | Social Determinants | Health Systems | Policy/Regulation | Global Governance | Government/Law | Health/Medicine | Science/Technology | Global -
ArticlePublication 2016Challenges of Prioritization
Cost-effectiveness analysis has traditionally been applied primarily to very specific interventions, such as drugs and …
Cost-effectiveness analysis has traditionally been applied primarily to very specific interventions, such as drugs and diagnostics; in addition, the evidence base drawn on for evaluating such interventions is relatively good, given the medical research industry surrounding their testing. However, with increasing success in controlling infectious diseases, many of the health challenges facing countries concern broad threats to health with multiple causes, such as obesity, where the relationship between policy action and health benefit is not…
Benefit-Cost Analysis | Cost-Effectiveness Analysis | Economics/Finance | Mental Health | Infectious Diseases | Priority Setting/Ethics | Chronic Disease/Risk | Health Systems | Health/Medicine | Global -
ArticlePublication 2015Broader Economic Impact of Vaccination: Reviewing and Appraising the Strength of Evidence
Economic evaluations of public health programs such as immunization often consider only direct health benefits and …
Economic evaluations of public health programs such as immunization often consider only direct health benefits and medical cost savings. Evidence linking immunization to important benefits in indicators such as childhood development, household behavior, and other macro-economic data are unclear. A conceptual framework of the pathways between immunization and these broader economic benefits was developed through expert consultation. The authors obtained articles from previous reviews, snowballing, and expert consultation, and associated them with one of the pathways and assessed them using modified Grading…
Evidence Synthesis | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Economics/Finance | Infectious Diseases | Preferences/Values | Priority Setting/Ethics | Costing Methods | Social Determinants | Education/Labor | Health/Medicine -
ArticlePublication 2010Alternative Strategies to Reduce Maternal Mortality in India: A Cost-Effectiveness Analysis
This article, published in PLoS Medicine, conducted a cost-effectiveness analysis of strategies to improve pregnancy …
This article, published in PLoS Medicine, conducted a cost-effectiveness analysis of strategies to improve pregnancy and childbirth safety in India. Country- and region-specific data were synthesized using a computer-based model that simulates the natural history of pregnancy and pregnancy-associated complications in individual women, and considers delivery location, attendant, and facility level. Model validation compared projected maternal indicators with empiric data. Strategies consisted of improving coverage of effective interventions that could be provided individually or packaged…
Evidence Synthesis | Cost-Effectiveness Analysis | Economics/Finance | Maternal/Reproductive Health | Mathematical Models | Microsimulation | Health/Medicine | Global | Asia & Pacific -
ArticlePublication 2022Comparative Health Systems Analysis of Differences in Catastrophic Health Expenditure
The growing burden of non-communicable diseases (NCDs) in low- and middle-income countries may have implications …
The growing burden of non-communicable diseases (NCDs) in low- and middle-income countries may have implications for health system performance in the area of financial risk protection, as measured by catastrophic health expenditure (CHE). This article compares non-communicable diseases catastrophic health expenditure to the CHE cases caused by communicable diseases across health systems to examine whether: (1) disease burden and catastrophic health expenditure are linked, (2) Catastrophic health expenditures secondary to NCDs disproportionately affect wealthier households and (3) whether the drivers…
Evidence Synthesis | Cost-Effectiveness Analysis | Economics/Finance | Infectious Diseases | Costing Methods | Chronic Disease/Risk | Health Systems | Health/Medicine | Global -
ArticlePublication 2022COVID-19 Response: The Need for Economic Evaluation
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be …
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be quantitatively weighed using economic evaluation, such as those between health and cost outcomes. Other types of dimensions, such as those involving equity or autonomy, can be harder to quantify but should be considered in a comprehensive health policy decision-making context nonetheless. The authors of this New England Journal of Medicine Perspectives article outline how methods of economic evaluation and decision…
Benefit-Cost Analysis | Cost-Effectiveness Analysis | Economics/Finance | Infectious Diseases | Priority Setting/Ethics | Policy/Regulation | Health/Medicine | Global | North America -
ArticlePublication 2022Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face …
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face of uncertainty. This study aimed to quantify consequences of approving therapies or pursuing further research. The authors used a cohort state-transition model for hospitalized patients with COVID-19 to estimate quality-adjusted life-years (QALYs) and costs associated with multiple drug regimens and usual care. For each they assessed immediate approval, use only in research, emergency use authorization or reject. They conducted cost-effectiveness…
Benefit-Cost Analysis | Value of Information | Economics/Finance | Infectious Diseases | State-Transition | Policy/Regulation | North America | Europe -
ReportPublication 2016DCP3: Reproductive, Maternal, Newborn, and Child Health
This report from the World Bank is the second volume of the Disease Control Priorities, …
This report from the World Bank is the second volume of the Disease Control Priorities, Third Edition (DCP3) series. It focuses primarily on maternal conditions, childhood illnesses, and malnutrition, addressing topics from maternal mortality and morbidity, to acute illness and undernutrition in children under five, to the transition to older childhood and the illnesses that accompany this transition. The Disease Control Priorities Network (DCP) promotes and supports the use of economic evaluation for priority setting…
Evidence Synthesis | Cost-Effectiveness Analysis | Economics/Finance | Maternal/Reproductive Health | Costing Methods | Health Outcomes | Child/Nutrition | Health Systems | Global Governance | Health/Medicine | Global -
ReportPublication 2016DCP3: Mental, Neurological, and Substance Use Disorders
This report from the World Bank is the fourth volume of the Disease Control Priorities, …
This report from the World Bank is the fourth volume of the Disease Control Priorities, Third Edition (DCP3) series. It discusses the prevalence of mental, neurological, and substance use disorders, as well as the associated disability and premature mortality that can accompany them. Despite the high social and economic burden of these diseases on individuals, families, and communities, these disorders have been systematically neglected, especially in low- and middle-income countries, and there has been limited…
Evidence Synthesis | Cost-Effectiveness Analysis | Economics/Finance | Mental Health | Costing Methods | Health Outcomes | Health Systems | Global Governance | Health/Medicine | Global